Long, complex synthetic DNA constructs enable precise customization of genetic material enabling researchers to engineer therapeutic interventions tailored to individual patients. The intricate design of synthetic DNA sequences facilitates the delivery of therapeutic genes and regulatory elements to optimize the efficacy and safety of cell and gene therapies. The ability to rapidly manipulate and design complex DNA sequences with fewer constraints on sequence complexity is crucial for unlocking the full potential of personalized medicine, bringing targeted and effective treatments to market faster.
In March of 2023, Elegen launched ENFINIA DNA, offering researchers linear synthetic DNA fragments that were 2x longer and 20x more accurate than the fragments available on the market. ENFINIA DNA is produced from Elegen’s proprietary cell-free manufacturing process and shipped NGS-verified at lengths up to 7kb in as few as 7 days. Following a successful early access program, Elegen is now launching new sequence acceptance criteria that will enable researchers to order the same high-accuracy long DNA with industry-leading sequence complexity.
In this webinar, members of the Elegen team will discuss improvements they have made to enable the cell-free synthesis of ENFINA DNA constructs that include a diverse range of complexities commonly used in the design and development of cell and gene therapies, including ITRs, LTRs, GC-rich promoters, hairpins, long homopolymers, short and long repeat regions, and regions with high or low GC content.